{"title":"Immune Checkpoint Inhibitors: A Step forward in Cancer Management","authors":"A. Signorile, M. Carratù","doi":"10.18689/mjo-1000112","DOIUrl":"https://doi.org/10.18689/mjo-1000112","url":null,"abstract":"Maria Rosaria Carratù1*, Maria Assunta Potenza1, Carmela Nacci1, Domenico De Rasmo2 and Anna Signorile3 1Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Policlinico, Piazza Giulio Cesare 11, Bari, Italy 2Institute of Biomembranes, Bioenergetics and Molecular Biotechnology, National Research Council (CNR), Bari, Italy 3 Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Policlinico, Piazza Giulio Cesare 11, Bari, Italy","PeriodicalId":419802,"journal":{"name":"Madridge Journal of Oncogenesis","volume":"389 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124799896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beta-Endorphin - Novel Anti-Tumor Activity","authors":"T. Shrihari","doi":"10.18689/mjo-1000110","DOIUrl":"https://doi.org/10.18689/mjo-1000110","url":null,"abstract":"Endorphins are endogenous morphine, neuropeptides produced in the pituitary gland. Beta-endorphin is an abundant endorphin, more potent than morphine, synthesized and stored in the anterior pituitary gland. Beta-endorphin, has got various mechanisms of actions such as analgesic activity, stress buster activity, anti-inflammatory activity, and immune stimulatory activity, because of these mechanisms of actions it can be useful in holistic preventive, therapeutic, health promotive and palliative management of cancer without adverse effects. This article highlights about the basic research findings of anti-tumor activity of beta-endorphin.","PeriodicalId":419802,"journal":{"name":"Madridge Journal of Oncogenesis","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125178588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ALK Fusion Protein Expression in Lung Adenocarcinoma and its Correlation with EGFR Protein Expression","authors":"B. Ladani, B. Raiya, Nupur Patel, H. Vora","doi":"10.18689/MJO-1000109","DOIUrl":"https://doi.org/10.18689/MJO-1000109","url":null,"abstract":"Aim: To determine ALK fusion protein and EGFR protein expression by Immunohistochemistry in lung adenocarcinoma. Materials and Method: In this retrospective study, ALK and EGFR expression was evaluated by immunohistochemistry in 101 Formalin Fixed Paraffin Embedded (FFPE) tissues of lung adenocarcinoma. Results: In this study 11% patients showed ALK fusion protein expression. In relation to clinical parameters, a higher positive expression was observed in patients with age <59, in male gender and tobacco users. Further, with pathological parameters a higher expression of ALK was observed in advanced stage and positive lymph node status. EGFR expression was noted in 72% patients. In relation to clinical parameters, higher EGFR expression was seen in patients with age >59 years, in male gender with tobacco habit. Further, with pathological parameters, a trend of higher EGFR expression was observed in patients with positive lymph node status (p=0.06). In this study 8% of patients had ALK and EGFR dual expression, which is uncommon. Conclusion: Small group of NSCLC patients harbour ALK rearrangements which are candidate for targeted therapy (Crizotinib). Moreover, co-expression of ALK with EGFR defines a specific subgroup of patients that needs distinct therapeutic strategies.","PeriodicalId":419802,"journal":{"name":"Madridge Journal of Oncogenesis","volume":"111 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134173108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Can hENT1 Predict Survival in Locally Advanced Pancreatic Carcinoma Received Gemcitabine Monotherapy?","authors":"H. Tawfik, Sarah Ahmed, E. Saad, W. M. Said","doi":"10.18689/mjo-1000108","DOIUrl":"https://doi.org/10.18689/mjo-1000108","url":null,"abstract":"Background: Pancreatic cancer is a very aggressive disease. 5-year survival rates remain low at 10% to 30% even with adjuvant therapy, as most patients will succumb to the disease secondary to high rate of local and systemic recurrences. Gemcitabine is one of the drugs of choice for the adjuvant treatment for patients with pancreatic cancer. The drug is transported into pancreatic cancer cells primarily by human equilibrative nucleoside transporter 1 (hENT1). Aim: The aim of this study was to assess and evaluate the predictive and prognostic value of hENT1 expression in advanced pancreatic cancer patients. Methods: prospective and retrospective study was conducted on 30 patients presented with advanced pancreatic cancer; Immuno-histochemical staining of tumor tissue was performed for detecting hENT1 expression. All the patients have been treated with gemcitabine based chemotherapy. Results: Sixty percent of patients had high hENT1 expression and 40% had low hENT1 expression. Overall survival after median follow up of 14 months showed that patients with high hENT1 expression had longer Overall survival than patients with low hENT1 expression and the difference was statistically significant (p=0.001) and (p=0.0025) respectively. Further, patients with high hENT1 expression showed longer disease free survival than patients with low hENT1 expression, and the difference was statistically significant (p=0.002). Conclusions: A high level of hENT1 expression is significantly associated with a longer survival in patients who received gemcitabine mono therapy. Hence, the study suggests hENT1 expression as potential assay for the prediction of response to gemcitabine based chemotherapy.","PeriodicalId":419802,"journal":{"name":"Madridge Journal of Oncogenesis","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131051738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jigna S Joshi, H. Vora, N. Ghosh, J. Goswami, T. Trivedi
{"title":"Protein Expression of DNA Damage Signaling Molecules in Patients with Oral Squamous Cell Carcinoma","authors":"Jigna S Joshi, H. Vora, N. Ghosh, J. Goswami, T. Trivedi","doi":"10.18689/MJO-1000107","DOIUrl":"https://doi.org/10.18689/MJO-1000107","url":null,"abstract":"Jigna S Joshi1, Hemangini H Vora2, Nandita R Ghosh3, Jignesh V Goswami4 and Trupti Trivedi1* 1Clinical Carcinogenesis Lab, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, India 2Immunohematology Lab, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, India 3Tumor biology Lab, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, India 4Department of Surgical Oncology, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, India","PeriodicalId":419802,"journal":{"name":"Madridge Journal of Oncogenesis","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127291901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}